Inovio Pharmaceuticals INO makes DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer and infectious ailments, using its proprietary optimized ...

Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...

The company reiterated its plan to submit the BLA for INO-3107 under the FDA's rolling submission process in mid-2025, aiming for FDA acceptance of the filing by year-end and a potential PDUFA date in ...

(RTTNews) - INOVIO (INO) announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respiratory Papillomatosis in the second half of 2024. This followed an Initial ...

Inovio (INO) announced data from a retrospective trial showing that the number of Recurrent Respiratory Papillomatosis , or RRP, patients meeting the criteria for a Complete Response, or CR, increased ...

INO is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of INO shares has decreased $0.01 since the market last closed. This is a 0.51% ...

Shares of Inovio Pharmaceuticals (NASDAQ:INO) gained ~4% in the morning hours on Tuesday after Piper Sandler initiated the DNA medicines developer with an Overweight recommendation, citing a potential ...

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced it will present new data on its lead product candidate INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), at several ...

Inovio Pharmaceuticals Inc (NASDAQ:INO) shares are trading lower by 40% to $2.23 during Friday’s session after the company priced a public offering of 10 million shares of common stock and ...